Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis

// De-Dong Cao 1 , Hui-Lin Xu 2 , Liang Liu 3 , Yong-Fa Zheng 1 , Si-Fa Gao 1 , Xi-Ming Xu 1 and Wei Ge 1 1 Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China 2 Department of Oncology, The Fifth Hospital of WuHan, WuHan, Hubei, China 3 Department of Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China Correspondence to: Wei Ge, email: // Keywords : hepatocellular carcinoma, thalidomide, TACE, meta-analysis, survival Received : October 12, 2016 Accepted : March 16, 2017 Published : March 29, 2017 Abstract Objective: Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC). This study aims to evaluate the clinical efficacy and safety of thalidomide and TACE in primary HCC. Methods: Randomized controlled trials(RCTs) about efficacy and safety of thalidomide combined with TACE for primary HCC were identified from the Cochrane Library, Pubmed, Embase, CNKI, and Wan Fang until August, 2016. The retrieved trials were reviewed and the data were extracted by two reviewers, independently. Combined analyses of survival rates, overall response rate(ORR), disease control rate(DCR), changes of KPS, parameters of cellular immunity and vascular endothelial growth factor(VEGF), and adverse events were performed using RevMan 5.3 software. Results: A total of 23 RCTs involving 1836 patients were included. The results showed that thalidomide plus TACE was significantly superior in increasing 6-month survival rate(OR=1.79, 95% CI:1.02-3.15, P =0.04), 1-year survival rate(OR=1.76, 95% CI:1.38-2.24, P <0.0001), 1.5-year survival rate(OR=4.72, 95% CI:2.64-8.43, P <0.001), 2-year survival rate(OR=1.78, 95% CI:1.37-2.30, P <0.001), ORR(OR=1.89, 95% CI:1.48-2.42, P <0.0001), DCR(OR=2.62, 95% CI:1.90-3.63, P <0.001), improvement in cellular immunity(MD=0.63, 95% CI:0.45-0.80, P <0.0001), and reduction of VEGF(MD=-119.71, 95% CI:-135.75—103.68, P <0.0001), when compared with TACE group. The incidences of gastrointestinal reactions, myelosuppression, and liver dysfunction were similar between combination group and TACE group( P >0.05). However, compared to TACE, the combination of thalidomide and TACE had a higher incidence of drug rash(OR=6.35, 95% CI:2.75-14.68, P <0.0001). Conclusion: Our findings suggest that thalidomide combined with TACE shows better clinical efficacy and tolerable adverse events in patients with primary HCC when compared with TACE alone.